PDE5 inhibitors enhance melanoma cell growth by activating cGMP pathways both in vitro and in vivo, thus indicating a link between PDE5 and cGMP pathways in melanoma cells (Dhayade et al., 2016). The gene discussed is PDE5A; the disease is melanoma.